


Figure S1: Markers of barrier permeability and endothelial damage in BAL, following LPS challenge: GSK2798745 v placebo

Model-adjusted median and 95% credible interval in BAL samples taken at baseline (2 hours post-first GSK2798745/placebo dose), and at 24 h after LPS challenge (26 h post first GSK2798745/placebo dose).






Figure S2: Markers of inflammation in bronchoalveolar lavage, following LPS challenge: GSK2798745 v placebo

Model-adjusted median and 95% credible interval in mean response in BAL samples taken at baseline (2 hours post-first GSK2798745/placebo dose), and at 24 h after LPS challenge (26 h post first GSK2798745/placebo dose).




Figure S3: Markers of barrier permeability and endothelial damage in blood, following LPS challenge: GSK2798745 v placebo

Model-adjusted median and 95% credible interval in blood samples taken at 2 h post-first GSK2798745/placebo dose (before LPS/saline challenge), and at 3, 8 and 26 h post-first GSK2798745/placebo dose (1, 6 and 24 h after LPS and saline challenges).




Figure S4: Markers of inflammation in blood, following LPS challenge: GSK2798745 v placebo
 Model-adjusted median and 95% credible interval in mean response in blood samples taken at 2 h post-first GSK2798745/placebo dose (before LPS/saline challenge), and at 3, 8 and 26 h post-first GSK2798745/placebo dose (1, 6 and 24 h after LPS and saline challenges).